Shorter chemo before transplant may cut severe side effects for blood cancer patients

NCT ID NCT04098393

Ongoing Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This study tests a condensed version of a chemotherapy regimen (busulfan, melphalan, fludarabine) plus an immune-suppressing drug (ATG) given before a donor stem cell transplant. The goal is to see if this shorter approach causes fewer severe side effects within 30 days after transplant. Adults with certain blood cancers, such as acute leukemia or high-risk myelodysplastic syndrome, may be eligible.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: busulfan, melphalan, fludarabine, and antithymocyte globulin
What this could lead to: If successful, this condensed regimen could make stem cell transplants safer for people with blood cancers by reducing severe side effects.
What could go wrong: This is a small, early-phase pilot study, so results may not apply broadly. The chemotherapy itself carries risks of serious toxicity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOLOGIC MALIGNANCIES

Contacts and locations

Locations

Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.